Morgan Stanley Nurix Therapeutics, Inc. Transaction History

Morgan Stanley

$1.35 Trillion
Q3 2024

A detailed history of Morgan Stanley transactions in Nurix Therapeutics, Inc. stock. As of the latest transaction made, Morgan Stanley holds 1,878,564 shares of NRIX stock, worth $37.3 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

1,878,564

Previous 1,989,700 5.59%

Holding current value

$37.3 Million

Previous $41.5 Million 1.56%

% of portfolio

0.0%

Previous 0.0%

19 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	SELL	$18.93 - $25.69 $2.1 Million - $2.86 Million	-111,136 Reduced 5.59%	1,878,564 $42.2 Million
Q2 2024 Oct 17, 2024	SELL	$12.02 - $21.3 $6.5 Million - $11.5 Million	-541,099 Reduced 21.38%	1,989,700 $41.5 Million
Q2 2024 Aug 14, 2024	SELL	$12.02 - $21.3 $6.5 Million - $11.5 Million	-541,099 Reduced 21.38%	1,989,700 $41.5 Million
Q1 2024 Oct 17, 2024	BUY	$7.77 - $15.66 $4.2 Million - $8.47 Million	541,099 Added 27.2%	2,530,799 $37.2 Million
Q1 2024 Aug 16, 2024	SELL	$7.77 - $15.66 $4.69 Million - $9.46 Million	-604,238 Reduced 19.27%	2,530,799 $37.2 Million
Q1 2024 May 15, 2024	SELL	$7.77 - $15.66 $4.69 Million - $9.46 Million	-604,238 Reduced 19.27%	2,530,799 $37.2 Million
Q4 2023 Aug 16, 2024	BUY	$4.25 - $10.71 $4.87 Million - $12.3 Million	1,145,337 Added 57.56%	3,135,037 $32.4 Million
Q4 2023 Feb 13, 2024	BUY	$4.25 - $10.71 $12.2 Million - $30.9 Million	2,881,624 Added 1137.13%	3,135,037 $32.4 Million
Q3 2023 Nov 15, 2023	BUY	$7.86 - $10.08 $348,323 - $446,705	44,316 Added 21.19%	253,413 $1.99 Million
Q2 2023 Aug 14, 2023	SELL	$8.7 - $13.28 $381,190 - $581,863	-43,815 Reduced 17.32%	209,097 $2.09 Million
Q1 2023 May 15, 2023	SELL	$8.56 - $13.26 $1.26 Million - $1.96 Million	-147,510 Reduced 36.84%	252,912 $2.25 Million
Q4 2022 Feb 14, 2023	SELL	$9.86 - $14.59 $789,983 - $1.17 Million	-80,120 Reduced 16.67%	400,422 $4.4 Million
Q3 2022 Nov 14, 2022	SELL	$12.33 - $19.81 $1.25 Million - $2.01 Million	-101,563 Reduced 17.45%	480,542 $6.26 Million
Q2 2022 Oct 27, 2022	SELL	$7.88 - $14.82 $778,181 - $1.46 Million	-98,754 Reduced 14.5%	582,105 $7.38 Million
Q2 2022 Aug 15, 2022	SELL	$7.88 - $14.82 $778,181 - $1.46 Million	-98,754 Reduced 14.5%	582,105 $7.38 Million
Q1 2022 Oct 27, 2022	BUY	$12.94 - $29.65 $1.28 Million - $2.93 Million	98,754 Added 16.96%	680,859 $9.54 Million
Q1 2022 May 13, 2022	BUY	$12.94 - $29.65 $7.69 Million - $17.6 Million	594,538 Added 688.75%	680,859 $9.54 Million
Q4 2021 Feb 14, 2022	SELL	$26.43 - $34.5 $1.41 Million - $1.84 Million	-53,252 Reduced 38.15%	86,321 $2.5 Million
Q3 2021 Nov 15, 2021	BUY	$22.71 - $36.69 $3.17 Million - $5.12 Million	139,573 New	139,573 $4.18 Million

Others Institutions Holding NRIX

# of Institutions

181

Shares Held

68.1M

Call Options Held

78K

Put Options Held

53.8K

View Full List

About Nurix Therapeutics, Inc.

Ticker NRIX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 47,147,800
Market Cap $935M
Description
Nurix Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapies for the treatment of cancer and immune disorders. The company develops NX-2127, an orally available Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies...

More about NRIX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

News

Stay updated on Morgan Stanley with notifications on news.

Account